2004년: 경북대학교 의과대학교 의학과 학사
2015년: 경북대학교 의과대학교 의학과 석사
2019년: 경북대학교 의과대학교 의학과 박사

2014.~2016. 8.차의과학대학교 부속 구미차병원 조교수
2023.~ 현재. Clinical Ultrasound, Editor-In-Chief

학회 및 학술활동
대한간학회 정회원, 편집위원
대한임상초음파학회, 평생회원, 간행이사
대한간암학회 평생회원
대한소화기학회 평생회원
대한소화기내시경학회 평생회원
유럽간학회(EASL) 회원
아시안태평양간학회(APASL) 회원

2017 The Liver Week, 우수 연제상 (Best Presentation Award)
2018 The Liver Week, 우수 연제상 (Best Presentation Award)

2020.3~2021.2 University of California San Diego 방문교수 (Visiting scholar)

• 1. Endoscopic Management of Rectal Dieulafoy’s lesion: A Case Series and Optimal Treatment
• 2. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
• 3. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy
• 4. Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease: A Korean nationwide, multicenter, retrospective, observational, cohort study
• 5. Early complications after percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1,843 ablations in 1,211 patients in a single centre: experience over 10 years
• 6. Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article
• 7. Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B
• 8. Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease
• 9. Association of low skeletal muscle mass with advanced liver fibrosis in patients with non-alcoholic fatty liver disease
• 10. Effects of Branched-Chain Amino Acid (BCAA) Supplementation on the Progression of Advanced Liver Disease: A Korean Nationwide, Multicenter, Prospective, Observational, Cohort Study
• 11. Expression of the Long Noncoding RNA GAS5 Correlates with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
• 12. Association between Atrial Fibrillation and Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
• 13. Plasma Long Noncoding RNA LeXis is a Potential Diagnostic Marker for Non-Alcoholic Steatohepatitis
• 14. Fibrosis-4 index as a predictor for mortality in hospitalised patients with COVID-19: a retrospective multicentre cohort study
• 15. Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease
• 16. Low Skeletal Muscle Mass Is a Risk Factor for Subclinical Atherosclerosis in Patients with Nonalcoholic Fatty Liver Disease
• 17. Association of Skeletal Muscle and Adipose Tissue Distribution with Histologic Severity of Non-Alcoholic Fatty Liver
• 18. Long-term effects of the changes in hepatic steatosis status on the risk of incident type 2 diabetes mellitus: A 15-year community-based prospective cohort study
• 19. Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease
• 20. Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification